CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $13.89M, lower than 95% of all stocks globally
- PositionOperating margin is -208.1%, lower than 95% of its Medical Devices peers (median 7.3%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
353.85MUSDvs all stocks (USD)
Revenue (TTM)
13.89MUSDvs all stocks (USD)
Profit Margin
-214.74%vs Medical Devices peers
52-Week Change
46.80%vs all stocks
Market Capitalization
353.85MUSDvs all stocks (USD)
Enterprise Value
300.40MUSDvs all stocks (USD)
Forward P/E
-15.10xvs Medical Devices peers
Price to Sales (TTM)
24.17xvs Medical Devices peers
Price to Book (MRQ)
23.99xvs Medical Devices peers
Enterprise to Revenue
21.63xvs Medical Devices peers
Enterprise to EBITDA
-10.16xvs Medical Devices peers
Gross Margin
51.36%vs Medical Devices peers
Profit Margin
-214.74%vs Medical Devices peers
Operating Margin
-208.07%vs Medical Devices peers
Return on Assets (TTM)
-132.47%vs Medical Devices peers
Return on Equity (TTM)
-335.06%vs Medical Devices peers
Revenue (TTM)
13.89MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2910USDUpdated Sep 27, 2026Quarterly Revenue Growth
9.90%vs Medical Devices peers
Gross Profit (TTM)
7.07MUSDvs all stocks (USD)
EBITDA (TTM)
-29.57MUSDvs all stocks (USD)
Net Income (TTM)
-29.83MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-27.82MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-16.28MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
13.55MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
6.38MUSDFY2025 · Dec 31, 2025Gross Profit
7.17MUSDFY2025 · Dec 31, 2025Operating Income
-25.52MUSDvs all stocks (USD)
Pre-tax Income
-25.29MUSDFY2025 · Dec 31, 2025Income Tax Expense
24.00KUSDFY2025 · Dec 31, 2025Net Income
-25.32MUSDFY2025 · Dec 31, 2025EBIT
-25.52MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-24.95MUSDFY2025 · Dec 31, 2025Research & Development
18.31MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
14.38MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
269.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-25.32MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-24.66MUSDFY2025 · Dec 31, 2025Free Cash Flow
-24.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
10.11MUSDFY2025 · Dec 31, 2025Income Tax Paid
9.00KUSDFY2025 · Dec 31, 2025Interest Paid
15.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-25.32MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
567.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
826.00KUSDFY2025 · Dec 31, 2025Other Non-cash Items
31.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-478.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
376.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-664.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-90.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-90.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
1.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-3.18MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
23.37MUSDFY2025 · Dec 31, 2025Shares Outstanding
50.03MSharesUpdated Sep 27, 2026Float Shares
29.74MSharesUpdated Sep 27, 2026Shares Short
1.90MSharesUpdated Sep 27, 2026Short Ratio
15.64daysvs all stocks
Short % of Shares Outstanding
5.05%vs all stocks
% Held by Insiders
30.14%vs all stocks
% Held by Institutions
9.74%vs all stocks
Total Cash (MRQ)
9.08MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.1810USDUpdated Sep 27, 2026Total Debt (MRQ)
687.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0522xvs Medical Devices peers
Current Ratio (MRQ)
3.35xvs Medical Devices peers
Book Value per Share (MRQ)
0.2630USDUpdated Sep 27, 2026Total Assets
18.16MUSDvs all stocks (USD)
Total Current Assets
16.67MUSDFY2025 · Dec 31, 2025Total Liabilities
4.90MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.50MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
477.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
4.43MUSDFY2025 · Dec 31, 2025Cash
10.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
10.11MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.50MUSDFY2025 · Dec 31, 2025Inventory
2.99MUSDFY2025 · Dec 31, 2025Accounts Payable
1.14MUSDFY2025 · Dec 31, 2025Short-term Debt
410.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
177.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
519.00KUSDFY2025 · Dec 31, 2025Long-term Debt
477.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
47.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-155.66MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
13.26MUSDvs all stocks (USD)
52-Week Low
4.38USDUpdated Sep 27, 202652-Week High
15.37USDUpdated Sep 27, 202652-Week Change
46.80%vs all stocks
50-Day MA
6.41USDUpdated Sep 27, 2026200-Day MA
6.83USDUpdated Sep 27, 2026Avg 10-Day Volume
388.09KSharesUpdated Sep 27, 2026Avg 30-Day Volume
203.54KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.11USDUpdated Sep 27, 2026Other Income / Expense
-44.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -208.1%, lower than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: -2.08Industry median: 0.07Industry P5: -0.73Peers compared: 102
Profit margin is -214.7%, lower than 95% of its Medical Devices peers (median 4.1%)Significant
Profit margin: -2.15Industry median: 0.04Industry P5: -1.45Peers compared: 102
Return on equity is -335.1%, lower than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: -3.35Industry median: 0.03Industry P5: -0.59Peers compared: 102
Return on assets is -132.5%, lower than 95% of its Medical Devices peers (median 1.7%)Significant
Return on assets: -1.32Industry median: 0.02Industry P5: -0.44Peers compared: 102
Price-to-book is 23.99×, higher than 95% of its Medical Devices peers (median 2.51×)Significant
Price-to-book: 23.99Industry median: 2.51Industry P95: 12.98Peers compared: 102
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 24.17Revenue Growth YoY: 0.10
High gross margins eroded by operating costsNotable
Gross Margin: 0.51Profit Margin: -2.15
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.54
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $13.89M, lower than 95% of all stocks globallySignificant
Revenue (USD): 13,891,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Cabaletta Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Orchestra BioMed Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhongfu Information Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityPartial Recovery After Sharp Decline
Sensorion SA
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityPartial Recovery After Sharp Decline
Farsoon Technologies Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityPartial Recovery After Sharp Decline